Dr. Daniels on Immunotherapy in Head and Neck Cancer

Gregory A. Daniels, MD, PhD
Published Online: Wednesday, Dec 06, 2017



Gregory A. Daniels, MD, PhD, medical oncologist, associate professor of medicine, UC San Diego Health, discusses the role of immunotherapy for patients with head and neck cancer.

According to Daniels, it is important to use genetics to discover what is driving the mutation. The next thing that happens with these targeted therapies is resistance. HER3 is activated at MAP-kinase resistance when you start turning off BRAF. There are ongoing studies looking at those combinations.

As far as immunotherapy is concerned, there is pembrolizumab (Keytruda), nivolumab (Opdivo), and others in the field. These have good activity, but often cause stable disease for a period of time, explains Daniels.
 


Gregory A. Daniels, MD, PhD, medical oncologist, associate professor of medicine, UC San Diego Health, discusses the role of immunotherapy for patients with head and neck cancer.

According to Daniels, it is important to use genetics to discover what is driving the mutation. The next thing that happens with these targeted therapies is resistance. HER3 is activated at MAP-kinase resistance when you start turning off BRAF. There are ongoing studies looking at those combinations.

As far as immunotherapy is concerned, there is pembrolizumab (Keytruda), nivolumab (Opdivo), and others in the field. These have good activity, but often cause stable disease for a period of time, explains Daniels.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x